Update Focus Interpretation：CANMAT/ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorders

doi:10.12114/j.issn.1007-9572.2018.00.408

Abstract

Abstract: With the development of society and the increase of priority given to mental health，the impact on patients caused by bipolar disorders is brought into focus. How to make a correct diagnosis and treatment is a big challenge to every psychiatrist. In this review，key content and changes for the CANMAT/ISBD 2018 guidelines for the management of patients with bipolar disorders are addressed. The main contents include the general highlights of the guidelines，the basis of bipolar disorders management，drug treatment and the role and recommendation of psychosocial intervention，hoping to give a hand to clinicians to better understand the new guidelines.

Key words: Bipolar disorder, Diagnosis, Treatment, Chronic disease management, Depressive episode, Manic episode, Hypomanic episode

摘要： 随着社会的发展和对精神卫生的重视，双相障碍对患者的影响越来越受到社会关注。如何做到正确诊断和合理治疗是每个临床医生所面对的重大难题。本文对《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》重点内容进行分析解读，主要内容包括指南总体亮点、疾病管理基础、药物治疗、心理社会干预的作用和推荐，以期为广大临床工作者提供新的指导方针。

关键词: 双相情感障碍, 诊断, 治疗, 慢病管理, 抑郁发作, 躁狂发作, 轻躁狂发作

CHEN Jun,FANG Yiru,XU Yifeng. Update Focus Interpretation：CANMAT/ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorders　[J]. Chinese General Practice, 2019, 22(2): 123-127. DOI: 10.12114/j.issn.1007-9572.2018.00.408.
陈俊,方贻儒,徐一峰. 《2018版加拿大抑郁和焦虑治疗网络/国际双相障碍学会双相障碍管理指南》的更新重点解读[J]. 中国全科医学, 2019, 22(2): 123-127. DOI: 10.12114/j.issn.1007-9572.2018.00.408.

References

［1］YATHAM L N，KENNEDY S H，O'DONOVAN C，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）guidelines for the management of patients with bipolar disorder：consensus and controversies［J］．Bipolar Disord，2005，7（Suppl 3）：5-69．DOI：10.1111/j.1399-5618.2005.00219.x.
［2］YATHAM L N，KENNEDY S H，O'DONOVAN C，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）guidelines for the management of patients with bipolar disorder：update 2007［J］．Bipolar Disord，2006，8（6）：721-739．DOI：10.1111/j.1399-5618.2006.00432.x.
［3］YATHAM L N，KENNEDY S H，SCHAFFER A，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）collaborative update of CANMAT guidelines for the management of patients with bipolar disorder：update 2009［J］．Bipolar Disord，2009，11（3）：225-255．DOI：10.1111/j.1399-5618.2009.00672.x.
［4］YATHAM L N，KENNEDY S H，PARIKH S V，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）collaborative update of CANMAT guidelines for the management of patients with bipolar disorder：update 2013［J］．Bipolar Disord，2013，15（1）：1-44．DOI：10.1111/bdi.12025.
［5］YATHAM L N，KENNEDY S H，PARIKH S V，et al．Canadian Network for Mood and Anxiety Treatments（CANMAT）and International Society for Bipolar Disorders（ISBD）2018 guidelines for the management of patients with bipolar disorder［J］．Bipolar Disord，2018，20（2）：97-170．DOI：10.1111/bdi.12609
［6］American Psychiatric Association，DSM-5 Task Force.Diagnostic and statistical manual of mental disorders：DSM-5?（5th ed.）［M］．Arlington：American Psychiatric Publishing，2013.
［7］FERRARI A J，CHARLSON F J，NORMAN R E，et al．Burden of depressive disorders by country，sex，age，and year：findings from the global burden of disease study 2010［J］．PLoS Med，2013，10（11）：e1001547．DOI：10.1371/journal.pmed.1001547.
［8］MERIKANGAS K R，AKISKAL H S，ANGST J，et al．Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication［J］．Arch Gen Psychiatry，2007，64（5）：543-552．DOI：10.1001/archpsyc.64.5.543.
［9］SCHAFFER A，ISOMETSA E T，TONDO L，et al．Epidemiology，neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder：part Ⅰ of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder［J］．Aust N Z J Psychiatry，2015，49（9）：785-802．DOI：10.1177/0004867415594427.
［10］MARANGELL L B，BAUER M S，DENNEHY E B，et al．Prospective predictors of suicide and suicide attempts in 1，556 patients with bipolar disorders followed for up to 2 years［J］．Bipolar Disord，2006，8（5 Pt 2）：566-575．DOI：10.1111/j.1399-5618.2006.00369.x.
［11］SMITH K A，CIPRIANI A.Lithium and suicide in mood disorders：updated meta-review of the scientific literature［J］．Bipolar Disord，2017，19（7）：575-586．DOI：10.1111/bdi.12543.
［12］WAGNER E H.Chronic disease management：what will it take to improve care for chronic illness?［J］．Eff Clin Pract，1998，1（1）：2-4.
［13］MICHALAK E E，MURRAY G，Collaborative Research Team to Study Psychosocial Issues in Bipolar Disorder（CREST.BD）．Development of the QoL.BD：a disorder-specific scale to assess quality of life in bipolar disorder［J］．Bipolar Disord，2010，12（7）：727-740．DOI：10.1111/j.1399-5618.2010.00865.x.
［14］DURGAM S，EARLEY W，LU K，et al．Global improvement with cariprazine in the treatment of bipolar Ⅰ disorder and schizophrenia：a pooled post hoc analysis［J］．Int J Clin Pract，2017，71（12）．DOI：10.1111/ijcp.13037.
［15］MORA E，PORTELLA M J，FORCADA I，et al．Persistence of cognitive impairment and its negative impact on psychosocial functioning in lithium-treated，euthymic bipolar patients：a 6-year follow-up study［J］．Psychol Med，2012，43（6）：1-10．DOI：10.1017/S0033291712001948.
［16］KOZICKY J M，TORRES I J，BOND D J，et al．Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar Ⅰ disorder［J］．Int Clin Psychopharmacol，2012，27（2）：91-99．DOI：10.1097/YIC.0b013e32834e3bea.
［17］PACCHIAROTTI I，BOND D J，BALDESSARINI R J，et al．The International Society for Bipolar Disorders（ISBD）task force report on antidepressant use in bipolar disorders［J］．Am J Psychiatry，2013，170（11）：1249-1262．DOI：10.1176/appi.ajp.2013.13020185.
［18］MCGIRR A，VOHRINGER P A，GHAEMI S N，et al．Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression：a systematic review and meta-analysis of randomised placebo-controlled trials［J］．Lancet Psychiatry，2016，3（12）：1138-1146．DOI：10.1016/S2215-0366（16）30264-4.
［19］于欣，方贻儒.中国双相障碍防治指南（第二版）［M］．北京：中华医学电子音像出版社，2015.
YU X，FANG Y R.Guidelines for the prevention and treatment of bipolar disorder in China（2nd edition）［M］．Beijing：Chinese Medical Multimedia Press，2015.
［20］REINARES M，SANCHEZ-MORENO J，FOUNTOULAKIS K N.Psychosocial interventions in bipolar disorder：what，for whom，and when［J］．J Affect Disord，2014，156：46-55．DOI：10.1016/j.jad.2013.12.017.
［21］GONZáLEZ ISASI A，ECHEBURúA E，LIMI?ANA J M，et al．Psychoeducation and cognitive-behavioral therapy for patients with refractory bipolar disorder：a 5-year controlled clinical trial［J］．Eur Psychiatry，2014，29（3）：134-141．DOI：10.1016/j.eurpsy.2012.11.002.
［22］MIKLOWITZ D J，OTTO M W，FRANK E，et al．Intensive psychosocial intervention enhances functioning in patients with bipolar depression：results from a 9-month randomized controlled trial［J］．Am J Psychiatry，2007，164（9）：1340-1347．DOI：10.1176/appi.ajp.2007.07020311.
［23］SCOTT J，PAYKEL E，MORRISS R，et al．Cognitive-behavioural therapy for severe and recurrent bipolar disorders：randomised controlled trial［J］．Br J Psychiatry，2006，188：313-320．DOI：10.1192/bjp.188.4.313.
［24］LAM D H，WATKINS E R，HAYWARD P，et al．A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder：outcome of the first year［J］．Arch Gen Psychiatry，2003，60（2）：145-152.
［25］MIKLOWITZ D J，CHUNG B.Family-focused therapy for bipolar disorder：reflections on 30 years of research［J］．Fam Process，2016，55（3）：483-499．DOI：10.1111/famp.12237.

[1]	PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988.
[2]	CHEN Dian, LONG Huanyu, CHU Lanhe, JIANG Yixia, GUO Wanjin, NIU Yang, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2026 Report [J]. Chinese General Practice, 2026, 29(21): 2913-2932.
[3]	YAN Wen, ZHANG Hanzhi, JIN Hua, QIAN Jie, YU Dehua. Study on the Diagnosis and Treatment Capacity for Depressive Disorders in Community Health Service Institutions in Shanghai [J]. Chinese General Practice, 2026, 29(20): 2790-2799.
[4]	CHEN Xiangyang, HUANG Hongmei, LI Sheyu. Prevention and Management of Adult Obesity: Progress and Trends from Six Keywords in 2025 [J]. Chinese General Practice, 2026, 29(20): 2753-2758.
[5]	CHENG Yu, HAN Shiyao, SUN Ping, XIANG Juan, YANG Hui, LI Dongze, ZHENG Li, LIAO Xiaoyang. Analysis of Socioeconomic and Demographic Challenges in Chronic Disease Management [J]. Chinese General Practice, 2026, 29(20): 2800-2807.
[6]	WANG Xuan, SHEN Ying, XI Qian, ZHAO Can, MO Yunjian, ZHANG Wenting. Research on Treatment Burden and Influencing Factors of Patients with Multimorbidity in Rural Township Health Centers in Guangxi Zhuang Autonomous Region [J]. Chinese General Practice, 2026, 29(20): 2808-2815.
[7]	ZHANG Xiaojuan, LIU Yang, PENG Bo, YE Yuan, ZHU Kun. Study on the Prevention and Treatment of Hypertension and Diabetes Mellitus in Community Hospital [J]. Chinese General Practice, 2026, 29(19): 2614-2620.
[8]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.
[9]	AN Xian, HUANG Peng, REN Jingjing. Investigation on the Cognition and Current Status of General Practitioners in the Multidisciplinary Diagnosis and Treatment of Medically Unexplained Symptoms [J]. Chinese General Practice, 2026, 29(18): 2472-2481.
[10]	General Practice Branch of Cross-straits Medicine Exchange Association, General Practice Branch of Zhejiang Medical Association, General Undifferentiated Disease Professional Committee of Zhejiang Society of Mathematical Medicine, Chinese Geriatrics Society. Expert Consensus on the Diagnosis, Treatment, and Management of Numbness (2025) [J]. Chinese General Practice, 2026, 29(18): 2433-2449.
[11]	CHEN Qiulong, CHEN Jia, FANG Jing, DAI Wei, YANG Qing. Application Status and Research Progress of Observer-reported Outcome [J]. Chinese General Practice, 2026, 29(18): 2561-2570.
[12]	FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453.
[13]	HEI Moran, MA Hui'e, XU Zecheng, YAN Shiyan, LI Ziyan, YANG Yi, JIN Jun, CHEN Zelin, GUO Yi, ZHAO Xue, ZHAO Tianyi. Comparison, Analysis and Considerations of Methods for Determining Clinical Questions in Domestic and International Clinical Practice Guideline Development Manuals [J]. Chinese General Practice, 2026, 29(18): 2554-2560.
[14]	LUAN Xiaoqing, SUN Jingjing, LI Xiaoling, WANG Manxia. Research Progress on Potential Biomarkers of Neuromyelitis Optica Spectrum Disorder [J]. Chinese General Practice, 2026, 29(17): 2418-2424.
[15]	YAO Dingye, LUO Guiping, SUN Junsheng, LI Hui. Research Progress on Identifying Bipolar Ⅱ Disorder and Depressive Disorder in Primary Care [J]. Chinese General Practice, 2026, 29(15): 2092-2099.